Crossmark

Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer

Crossref DOI link: https://doi.org/10.1038/s41591-018-0101-z

Published Online: 2018-07-16

Published Print: 2018-09

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Kim, Seung Tae

Cristescu, Razvan https://orcid.org/0000-0002-9978-0339
Bass, Adam J.

Kim, Kyoung-Mee https://orcid.org/0000-0002-1162-9205
Odegaard, Justin I.

Kim, Kyung https://orcid.org/0000-0002-7712-3135
Liu, Xiao Qiao https://orcid.org/0000-0002-6371-6503
Sher, Xinwei https://orcid.org/0000-0003-3977-3695
Jung, Hun

Lee, Mijin

Lee, Sujin

Park, Se Hoon

Park, Joon Oh

Park, Young Suk

Lim, Ho Yeong

Lee, Hyuk

Choi, Mingew

Talasaz, AmirAli

Kang, Peter Soonmo

Cheng, Jonathan

Loboda, Andrey https://orcid.org/0000-0003-4239-184X
Lee, Jeeyun https://orcid.org/0000-0002-4911-6165
Kang, Won Ki
License Information

Text and Data Mining valid from 2018-07-16
More Information

Article History

Received: 19 December 2017

Accepted: 15 May 2018

First Online: 16 July 2018

Competing interests

: R.C., X.Q.L., X.S., J.C., P.S.K., and A.L. are employees of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. J.I.O. and A.T. are employees of Guardant Health, USA.